Diffusion Pharmaceuticals Stock Earnings Per Share
| DFFNDelisted Stock | USD 3.27 0.17 5.48% |
Diffusion Pharmaceuticals fundamentals help investors to digest information that contributes to Diffusion Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Diffusion Stock. The fundamental analysis module provides a way to measure Diffusion Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Diffusion Pharmaceuticals stock.
Diffusion |
Diffusion Pharmaceuticals Company Earnings Per Share Analysis
Diffusion Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Diffusion Pharmaceuticals Earnings Per Share | (7.11) X |
Most of Diffusion Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Diffusion Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Diffusion Pharmaceuticals has an Earnings Per Share of -7.11 times. This is 184.95% lower than that of the Biotechnology sector and 48.43% higher than that of the Health Care industry. The earnings per share for all United States stocks is notably higher than that of the company.
Diffusion Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Diffusion Pharmaceuticals' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Diffusion Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Diffusion Pharmaceuticals by comparing valuation metrics of similar companies.Diffusion Pharmaceuticals is currently under evaluation in earnings per share category among its peers.
Diffusion Fundamentals
| Return On Equity | -0.64 | |||
| Return On Asset | -0.38 | |||
| Current Valuation | (6.02 M) | |||
| Shares Outstanding | 2.04 M | |||
| Shares Owned By Insiders | 0.23 % | |||
| Shares Owned By Institutions | 10.27 % | |||
| Number Of Shares Shorted | 2.54 K | |||
| Price To Earning | (0.60) X | |||
| Price To Book | 0.51 X | |||
| EBITDA | (15.97 M) | |||
| Net Income | (15.59 M) | |||
| Cash And Equivalents | 25.86 M | |||
| Cash Per Share | 12.68 X | |||
| Total Debt | 67.89 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 11.59 X | |||
| Book Value Per Share | 6.97 X | |||
| Cash Flow From Operations | (14.97 M) | |||
| Short Ratio | 0.29 X | |||
| Earnings Per Share | (7.11) X | |||
| Target Price | 40.0 | |||
| Number Of Employees | 13 | |||
| Beta | 1.76 | |||
| Market Capitalization | 8.98 M | |||
| Total Asset | 22.64 M | |||
| Retained Earnings | (145.6 M) | |||
| Working Capital | 20.22 M | |||
| Current Asset | 3.29 M | |||
| Current Liabilities | 3.68 M | |||
| Z Score | 69.08 | |||
| Net Asset | 22.64 M |
About Diffusion Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Diffusion Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diffusion Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diffusion Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Diffusion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Diffusion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Diffusion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Diffusion Stock
Moving against Diffusion Stock
| 0.87 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
| 0.81 | JPM | JPMorgan Chase Fiscal Year End 10th of January 2025 | PairCorr |
| 0.81 | CSCO | Cisco Systems Aggressive Push | PairCorr |
| 0.79 | WMT | Walmart Aggressive Push | PairCorr |
| 0.79 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
The ability to find closely correlated positions to Diffusion Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Diffusion Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Diffusion Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Diffusion Pharmaceuticals to buy it.
The correlation of Diffusion Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Diffusion Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Diffusion Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Diffusion Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Diffusion Stock
If you are still planning to invest in Diffusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Diffusion Pharmaceuticals' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |